Core Viewpoint - Aardvark Therapeutics has received IRB approval for an amended protocol in its Phase 3 HERO trial, allowing participation of children aged 7 and older with Prader-Willi Syndrome (PWS) in the United States, aiming to enhance access and capture the potential impact of ARD-101 on hyperphagia in this population [1][2][3] Group 1: Trial Details - The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled study assessing ARD-101 for hyperphagia in PWS patients, with plans to enroll 90 patients across multiple countries including the U.S., Australia, Canada, the UK, and South Korea [4] - The primary endpoint of the trial is the change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12, with secondary measures including changes in Caregiver Global Impression of Severity (CaGI-S) and Clinical Global Impression of Severity (CGI-S) scores [4] Group 2: Drug Information - ARD-101 is a gut-restricted small molecule agonist targeting specific taste receptors, stimulating the release of gut-peptide hormones like GLP-1 and cholecystokinin (CCK) to mediate hunger [5] - The drug has shown potential in reducing hunger both alone and in combination with existing GLP-1 therapies, and has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for PWS [5][6] Group 3: Company Overview - Aardvark Therapeutics is focused on developing small-molecule therapeutics aimed at suppressing hunger for the treatment of PWS and other metabolic diseases, with ARD-101 being the lead compound in Phase 3 clinical development [7] - The company is also working on ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials to address limitations of current GLP-1 therapies [8]

Core Insights - Aardvark Therapeutics is progressing with its Phase 3 HERO trial for ARD-101, targeting hyperphagia in Prader-Willi syndrome (PWS), with topline data expected in Q3 2026 [1][4][6] Group 1: Clinical Trial Progress - The first patient has been dosed in Australia, and regulatory clearance for enrollment has been received in Canada and the UK [1][2] - Strong enrollment is reported in the US, with all patients from the completed 12-week trial participating in the Open Label Extension trial, indicating high patient engagement [2][3] - Aardvark anticipates that it will not need to activate previously planned sites in the EU to meet enrollment goals for the HERO trial [2] Group 2: Trial Details - The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled study enrolling 90 patients across multiple countries [4] - The primary endpoint is the change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12, with secondary measures including caregiver and clinical global impressions of severity [4] Group 3: Product Information - ARD-101 is a gut-restricted small molecule agonist that stimulates the release of gut-peptide hormones to mediate hunger, showing potential to reduce hunger when used alone or with GLP-1 therapies [5][6] - The FDA has granted ARD-101 Orphan Drug Designation and Rare Pediatric Disease Designation for PWS [5] Group 4: Company Overview - Aardvark Therapeutics focuses on developing small-molecule therapeutics to suppress hunger for metabolic diseases, with ARD-101 as its lead compound in clinical development for hyperphagia associated with PWS [7][8]

Core Insights - Soleno Therapeutics presented new data on VYKAT XR (diazoxide choline) extended-release tablets at the 2025 International Prader-Willi Syndrome Conference, highlighting its potential benefits for individuals with Prader-Willi Syndrome (PWS) [1][2] Group 1: Efficacy of VYKAT XR - VYKAT XR significantly reduces hyperphagia symptoms in PWS patients managed with strict food controls, showing statistically significant reductions in HQ-CT Total scores (p ≤ 0.0001) [5] - Participants in highly food-restricted environments benefited from VYKAT XR treatment similarly to those in less restricted environments, indicating broad applicability of the treatment [5] Group 2: Safety and Efficacy in Co-Morbid Conditions - 60% of study participants had evidence of pre-diabetes or diabetes (PD/DM) at baseline, with efficacy outcomes at Week 156 showing similar results for both PD/DM and normoglycemic groups (p<0.0001) [7] - Although a higher proportion of hyperglycemia-related adverse events were reported in the PD/DM group (42.7% vs 24.0%), these events were generally manageable, and treatment discontinuation rates were low (4.0% in PD/DM vs 6.0% in normoglycemic) [8][9] Group 3: Background on Prader-Willi Syndrome - Prader-Willi Syndrome is a rare genetic neurodevelopmental disorder affecting approximately 1 in every 15,000 live births, characterized by hyperphagia, which can lead to severe health complications [10][11] - Hyperphagia in PWS can result in significant mortality and long-term co-morbidities such as diabetes, obesity, and cardiovascular disease [12] Group 4: Product Information - VYKAT XR was approved by the FDA on March 26, 2025, and is indicated for the treatment of hyperphagia in adults and pediatric patients aged 4 years and older with PWS [13][18]